GLP-1 receptor expression and beta-cell mass in patients with type 2 diabetes

Phase 2

Recruiting

• Conditions: Diabetes Mellitus type 2; Diabetes type 2; 10018424

• Registration Number: NL-OMON55656
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 28

Inclusion Criteria

Scheduled for partial or complete pancreatectomy at Radboudumc

Exclusion Criteria

1.. Breast feeding, 2. Pregnancy or the wish to become pregnant within 6
months, 3. Creatinine clearance below 40ml/min, 4. Age > 18 years, 5. Liver
disease defined as aspartate aminotransferase or alanine aminotransferase level
of more than three times the upper limit of normal range, 6. Previous treatment
with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV
inhibitors in the past 3 months

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- AIM 1: Establish the relation between exendin uptake and BCM under various<br /><br>levels of glycaemic control<br /><br>- AIM2: Assess the specificity of exendin uptake during the progression of T2D</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- AIM 3: Establish the relation between BCM and beta-cell function in patients<br /><br>with T2D<br /><br>- AIM 4: Correlate ex vivo exendin uptake in GLP-1R positive tissues with<br /><br>GLP-1R gene expression profiles </p><br>